In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 3.87 below Tonix Pharmaceuticals Holding Corp average.

Within Major Pharmaceutical Preparations industry 170 other companies have achieved higher Quick Ratio than Tonix Pharmaceuticals Holding in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 524 to 641.

Explain Quick Ratio?
How much Cash & cash equivalents TNXP�s has?
What are TNXP�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/TNXP/financial-strength

https://api.csimarket.com/api/v1/companies/TNXP/fundamentals

https://api.csimarket.com/api/v1/companies/TNXP/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

TNXP Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	99.83 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-14.34 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	3.87	Subscribe	Subscribe	Subscribe	Subscribe
TNXP's Total Ranking	# 641	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	36.51 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-7.63 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 171
Healthcare Sector	# 272
Overall Market	# 641

Quick Ratio Statistics
High	Average	Low
27.24	8.25	0.03
(Mar 31 2021)		(Jun 30 2013)

Financial Statements
Tonix Pharmaceuticals Holding 's Current Liabilities	$ 42 Millions	Visit TNXP's Balance sheet
Tonix Pharmaceuticals Holding 's Cash & cash equivalent	$ 163 Millions	Visit TNXP's Balance sheet
Source of TNXP's Sales		Visit TNXP's Sales by Geography

Cumulative Tonix Pharmaceuticals Holding 's Quick Ratio

TNXP's Quick Ratio for the trailling 12 Months

TNXP Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	88.95 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	34.12 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	5.49	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3544	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	18.7 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-3.59 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to TNXP Financial Strength Comparisons >> Go to Compare TNXP Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2026 to $42.03 millions, cumulative Quick Ratio decreased to 5.49 below the Tonix Pharmaceuticals Holding Corp average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 420 other companies have achieved higher Quick Ratio than Tonix Pharmaceuticals Holding . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2795 to 3544.

Explain Quick Ratio?
How much Cash & cash equivalents TNXP�s has?
What are TNXP�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 421
Healthcare Sector	# 854
Within the Market	# 3544

trailing twelve months Quick Ratio Statistics
High	Average	Low
16.41	8.53	0.54
(Sep 30 2021)		(Jun 30 2024)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Bicycle Therapeutics Plc	10.57	$ 469.928 Millions	$ 44.459 Millions
Lipocine Inc	10.55	$ 21.455 Millions	$ 2.034 Millions
Cyclerion Therapeutics Inc	10.32	$ 456.221 Millions	$ 44.197 Millions
Lexicon Pharmaceuticals Inc	10.31	$ 183.203 Millions	$ 17.773 Millions
Adicet Bio Inc	10.28	$ 174.779 Millions	$ 16.996 Millions
Nuvectis Pharma inc	9.91	$ 140.707 Millions	$ 14.193 Millions
Renovorx Inc	9.76	$ 20.404 Millions	$ 2.091 Millions
Aprea Therapeutics Inc	9.52	$ 37.846 Millions	$ 3.975 Millions
Rezolute Inc	9.51	$ 89.999 Millions	$ 9.463 Millions
Ideaya Biosciences Inc	8.70	$ 838.541 Millions	$ 96.405 Millions
First Tracks Biotherapeutics Inc	8.60	$ 155.627 Millions	$ 18.090 Millions
Bicara Therapeutics Inc	7.99	$ 442.346 Millions	$ 55.368 Millions
Arvinas Inc	7.98	$ 558.400 Millions	$ 70.000 Millions
Wave Life Sciences Ltd	7.87	$ 431.012 Millions	$ 54.760 Millions
Rigel Pharmaceuticals Inc	7.79	$ 224.456 Millions	$ 28.806 Millions
Cytomx Therapeutics Inc	7.64	$ 347.980 Millions	$ 45.532 Millions
Atea Pharmaceuticals Inc	7.64	$ 191.199 Millions	$ 25.025 Millions
Viking Therapeutics Inc	7.17	$ 959.813 Millions	$ 133.897 Millions
Scynexis Inc	7.09	$ 47.165 Millions	$ 6.652 Millions
Lb Pharmaceuticals Inc	7.03	$ 215.075 Millions	$ 30.573 Millions
Zentalis Pharmaceuticals Inc	7.03	$ 228.893 Millions	$ 32.539 Millions
Quoin Pharmaceuticals Ltd	6.95	$ 33.184 Millions	$ 4.776 Millions
Vera Therapeutics Inc	6.89	$ 384.042 Millions	$ 55.775 Millions
Nuvation Bio Inc	6.73	$ 663.370 Millions	$ 98.559 Millions
Arcturus Therapeutics Holdings Inc	6.52	$ 184.817 Millions	$ 28.345 Millions
Moonlake Immunotherapeutics	6.50	$ 379.704 Millions	$ 58.430 Millions
Camp4 Therapeutics Corporation	6.27	$ 124.522 Millions	$ 19.865 Millions
Cartesian Therapeutics Inc	6.12	$ 122.975 Millions	$ 20.088 Millions
Summit Therapeutics Inc	5.71	$ 629.899 Millions	$ 110.226 Millions
Nurix Therapeutics Inc	5.51	$ 720.458 Millions	$ 130.742 Millions

Date modified: 2026-11-10T13:47:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.